Modality
siRNA
MOA
VEGFi
Target
PI3Kα
Pathway
Cell Cycle
PsA
Development Pipeline
Preclinical
Sep 2020
→ Aug 2025
PreclinicalCurrent
NCT04479409
2,256 pts·PsA
2020-09→2025-08·Active
2,256 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-177mo agoInterim· PsA
2026-01-133mo agoPDUFA· PsA
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
Preclinical
Active
Catalysts
Interim
2025-08-17 · 7mo ago
PsA
PDUFA
2026-01-13 · 3mo ago
PsA
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04479409 | Preclinical | PsA | Active | 2256 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |